Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director B Lynne Parshall sold 8,334 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $75.00, for a total value of $625,050.00. Following the completion of the sale, the director now owns 61,011 shares of the company’s stock, valued at $4,575,825. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

B Lynne Parshall also recently made the following trade(s):

  • On Wednesday, February 27th, B Lynne Parshall sold 8,333 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $70.00, for a total value of $583,310.00.

IONS stock traded up $0.83 during midday trading on Thursday, reaching $77.44. The company’s stock had a trading volume of 1,223,900 shares, compared to its average volume of 989,482. The company has a quick ratio of 7.85, a current ratio of 7.88 and a debt-to-equity ratio of 0.53. Ionis Pharmaceuticals Inc has a 1 year low of $39.07 and a 1 year high of $78.20. The firm has a market cap of $10.60 billion, a price-to-earnings ratio of 26.16 and a beta of 2.40.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, February 27th. The company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $2.20. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. The business had revenue of $192.00 million for the quarter, compared to analyst estimates of $159.59 million. During the same quarter last year, the firm posted ($0.03) earnings per share. The business’s revenue was up 14.3% compared to the same quarter last year. Research analysts expect that Ionis Pharmaceuticals Inc will post -0.05 EPS for the current year.

A number of analysts recently issued reports on the company. Piper Jaffray Companies raised their price target on Ionis Pharmaceuticals to $60.00 and gave the stock a “neutral” rating in a research report on Thursday, February 28th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, December 6th. ValuEngine upgraded Ionis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 28th. BMO Capital Markets raised their price target on Ionis Pharmaceuticals from $70.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, February 28th. Finally, Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $60.57.

Hedge funds have recently added to or reduced their stakes in the business. Huntington National Bank boosted its holdings in Ionis Pharmaceuticals by 159.3% in the fourth quarter. Huntington National Bank now owns 638 shares of the company’s stock worth $34,000 after acquiring an additional 392 shares in the last quarter. Essex Savings Bank purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $39,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $43,000. Daiwa Securities Group Inc. increased its position in shares of Ionis Pharmaceuticals by 29.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock valued at $48,000 after buying an additional 200 shares in the last quarter. Finally, Portfolio Solutions LLC purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 84.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals Inc (IONS) Director B Lynne Parshall Sells 8,334 Shares” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2019/03/14/ionis-pharmaceuticals-inc-ions-director-b-lynne-parshall-sells-8334-shares.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Article: Percentage Decliners

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.